Website
News25/Ratings8
News · 26 weeks37-67%
2025-10-262026-04-19
Mix1790d
- Insider6(35%)
- SEC Filings4(24%)
- Other3(18%)
- Earnings3(18%)
- Dividends1(6%)
Latest news
25 items- PRembecta to Report Fiscal Second Quarter Financial ResultsPARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal second quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, May 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)
- SECEmbecta Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Embecta Corp. (0001872789) (Filer)
- PRembecta Announces Definitive Agreement to Acquire Owen Mumford Holdings LimitedPARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("Embecta") (NASDAQ:EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited ("Owen Mumford"), a privately held, UK‑based innovator and manufacturer of medical devices and drug‑delivery technologies, in a transaction valued at up to £150 million. Under the terms of the agreement, embecta will acquire Owen Mumford for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing net cash), and up to an additional £50 million in performance-based payments based on net sales of the A
- INSIDERDirector Anderson Carrie L was granted 22,841 shares, increasing direct ownership by 55% to 64,581 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Hombach Robert J. was granted 22,841 shares, increasing direct ownership by 55% to 64,587 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Morris Milton Mayo was granted 22,841 shares, increasing direct ownership by 61% to 60,121 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Prange Karen was granted 22,841 shares, increasing direct ownership by 55% to 64,581 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Pomeroy Claire was granted 22,841 shares, increasing direct ownership by 53% to 66,127 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- INSIDERDirector Reidy Christopher R was granted 22,841 shares, increasing direct ownership by 48% to 70,122 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)
- SECEmbecta Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Embecta Corp. (0001872789) (Filer)
- PRembecta names new Chairman of the Board and Lead Independent DirectorPARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the "Board") of embecta has elected Devdatt "Dev" Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board due to several commitments outside of his service to the Company. Kurdikar, 57, joined BD (Becton, Dickinson and Company) in 2021 to lead the diabete
- SECSEC Form 10-Q filed by Embecta Corp.10-Q - Embecta Corp. (0001872789) (Filer)
- SECEmbecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Embecta Corp. (0001872789) (Filer)
- PREmbecta Corp. Reports First Quarter Fiscal 2026 Financial ResultsPARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be
- PRembecta Announces Quarterly Cash DividendPARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)
- SECSEC Form DEFA14A filed by Embecta Corp.DEFA14A - Embecta Corp. (0001872789) (Filer)
- PRembecta to Report Fiscal First Quarter Financial ResultsPARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11
- PRembecta to Participate at the J.P. Morgan 2026 Healthcare ConferencePARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ:EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be accessible under the "News & Events" section of the Company's investor relations website at investors.embecta.com. About embectaembecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the glo
- SECSEC Form DEFA14A filed by Embecta Corp.DEFA14A - Embecta Corp. (0001872789) (Filer)
- SECSEC Form DEF 14A filed by Embecta Corp.DEF 14A - Embecta Corp. (0001872789) (Filer)
- INSIDERAmendment: SEC Form 4 filed by SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z4/A - Embecta Corp. (0001872789) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by SVP and CFO Elguicze Jacob4/A - Embecta Corp. (0001872789) (Issuer)
- INSIDERChief Accounting Officer Roth Anthony M. was granted 32,817 shares and covered exercise/tax liability with 1,881 shares, increasing direct ownership by 188% to 47,415 units (SEC Form 4)4 - Embecta Corp. (0001872789) (Issuer)